Vincere Biosciences

Website

Vincere Biosciences Increase mitophagy. Conquer disease. By doing so, we aim to transform the lives of hundreds of millions of patients across the globe.

Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. Our innovative approach focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such as mitophagy. With the potential to be groundbreaking, these small molecules could become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. We welcome you to follow our page and other social media platforms for more content about our company, our dedicated team, and the science that drives what we do.

09/14/2026

Mitochondria Monday
This week: true or false?

• Is USP30 a negative regulator of mitophagy?
• Is broad mitochondrial removal better than selectively targeting damaged mitochondria?
• Could enhancing mitophagy complement other therapies being developed for neurodegenerative diseases?

09/10/2026

Vincere has received a $2.7 million NIH/NIDDK Direct Phase II SBIR award to advance our USP30 program through IND-enabling studies for acute kidney injury (AKI).

AKI remains a major unmet medical need, affecting more than 13 million people globally each year. Mortality rises substantially with disease severity, with 90-day mortality approaching 40% in patients with severe AKI. Yet there are still no approved therapies that directly modify the course of the disease.

At Vincere, we are developing therapies targeting USP30 and mitophagy to enhance the clearance of damaged mitochondria and restore mitochondrial health.

As our lead program advances into the clinic for Parkinson’s disease, this funding enables us to expand our pipeline with a second development candidate optimized for kidney exposure, where mitochondrial dysfunction is also a key driver of disease.

We’re incredibly grateful to the NIH, NIDDK, and all of the public and private funders and partners who have supported Vincere over the years. Their continued support has been instrumental in helping us translate mitochondrial biology into new medicines.

Mitochondria Monday - and the science of aging.The science of aging is key to changing the future of neurodegeneration, ...
09/07/2026

Mitochondria Monday - and the science of aging.

The science of aging is key to changing the future of neurodegeneration, including the therapies we develop here at Vincere Biosciences.

Whether it’s dysfunctional mitochondria, impaired proteostasis, or chronic inflammation, aging is the force that pushes vulnerable cells toward disease.

Genetics matter, environment is important, but for the vast majority of neurodegenerative disease, age remains the single greatest risk factor (and a modifiable one).

What do Parkinson's disease and the immune system have in common?More than you might think.They both rely on healthy mit...
09/02/2026

What do Parkinson's disease and the immune system have in common?

More than you might think.
They both rely on healthy mitochondria.

And they both depend on mitophagy - the cellular recycling process that removes damaged mitochondria before they compromise cell function.

Emerging research suggests that USP30 plays a role in immune cells such as CD8+ T cells.

While at Vincere Biosciences, we're developing therapies that enhance mitophagy to address neurodegenerative diseases such as Parkinson's disease, the research shows that mitochondrial quality control is fundamental across different cell types.

What came first - mitochondria or dinosaurs? 🦖Mitochondria. By a long stretch.1.45 billion years ago, a bacterium entere...
09/01/2026

What came first - mitochondria or dinosaurs? 🦖
Mitochondria. By a long stretch.

1.45 billion years ago, a bacterium entered another cell and never left.
That single event - endosymbiosis - gave rise to mitochondria as we know them today.

It happened only once in all of evolution, yet every known animal (including dinosaurs), plant, fungus, and many protists inherited mitochondria from that same ancestral moment.

At Vincere Biosciences, we study what happens when that ancient partnership breaks down. When mitochondria are damaged and not efficiently cleared through mitophagy, cellular health begins to decline - a process linked to neurodegenerative diseases such as Parkinson's disease.

Check the graphic to learn more. 🔬

08/31/2026

For Mitochondria Monday, the team asked me what drives me crazy about the way people talk about mitochondria.

Two things came to mind immediately:

1. We keep drawing one mitochondrion per cell, when a cell can contain hundreds to thousands of them. Mitochondria are far more numerous, dynamic, and biologically interesting than the textbook “powerhouse” story suggests.

2. “Mitochondria are the powerhouse of the cell” is a bit like calling a human a carbon-dioxide generator for plants: technically connected to reality, but absurdly reductive.

Yes, humans produce CO₂. Yes, plants use it. But reducing a human being to that output ignores almost everything else humans do. In the same way, mitochondria produce ATP. But ATP production is a byproduct of their REAL function: Survival and Propagation.

From an evolutionary perspective, survival and propagation are THE fundamental pressures shaping mitochondrial biology. In the context of their symbiotic relationship with their host cells, they are involved in metabolism, redox regulation, calcium signaling, apoptosis, biosynthesis, immune signaling, and making sure their host cells stay healthy.

Here’s my rant.

08/30/2026

Companies not using AI risk falling behind.

But what actually makes an AI-enabled biotech defensible?

Is it access to better models?
More data?
Proprietary knowledge?

Check out my take on what really creates defensibility in an AI-enabled biotech.

08/29/2026

Aging is not simply... getting older.
It is a complex biological process shaped by changes happening across cells, tissues, and organ systems over time.

At Vincere Biosciences, we fight age-related disease by targeting mitophagy - the process responsible for removing damaged mitochondria and maintaining cellular health.

Check out the video of our team members answering the question:
Aging is not simply… what?

08/28/2026

What if your mitochondria went on strike for just one day?
No ATP. No energy. No cellular cleanup. No business as usual.

So what else would happen if they stopped doing their jobs?
We asked the Vincere Biosciences team this question.

Watch the video to hear what they said.

08/27/2026

If your mitochondria could text your cells, what would the message say?
“Running low on energy”?
“Damage detected”?
“Time to clean up”?

We asked the Vincere Biosciences team: what would your mitochondria say to your cells?
Watch the video to hear their answers.

Address

Boston, MA

Website

,

Alerts

Be the first to know and let us send you an email when Vincere Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category